Yingwan Luo

426 total citations
29 papers, 244 citations indexed

About

Yingwan Luo is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Yingwan Luo has authored 29 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 11 papers in Genetics and 8 papers in Oncology. Recurrent topics in Yingwan Luo's work include Acute Myeloid Leukemia Research (22 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Vascular Tumors and Angiosarcomas (4 papers). Yingwan Luo is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers) and Vascular Tumors and Angiosarcomas (4 papers). Yingwan Luo collaborates with scholars based in China, United States and Hong Kong. Yingwan Luo's co-authors include Hongyan Tong, Jie Jin, Liya Ma, Xinping Zhou, Chen Mei, Yanling Ren, Keqing Shi, Li Ye, Ming‐Hua Zheng and Wen‐Yue Liu and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yingwan Luo

27 papers receiving 244 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yingwan Luo China 8 113 79 63 56 55 29 244
Christian Hosius Germany 7 59 0.5× 84 1.1× 25 0.4× 47 0.8× 27 0.5× 19 228
Samuel Quentin France 7 182 1.6× 132 1.7× 17 0.3× 87 1.6× 34 0.6× 9 288
Carlos Hader United States 5 215 1.9× 67 0.8× 31 0.5× 114 2.0× 51 0.9× 7 299
Oriana Miltiadous United States 3 114 1.0× 17 0.2× 22 0.3× 35 0.6× 17 0.3× 7 190
Sheng‐Chieh Chou Taiwan 8 108 1.0× 132 1.7× 9 0.1× 26 0.5× 57 1.0× 27 253
Yazan Migdady United States 10 84 0.7× 28 0.4× 27 0.4× 45 0.8× 38 0.7× 19 239
Yusuke Shiozawa Japan 9 82 0.7× 107 1.4× 10 0.2× 48 0.9× 31 0.6× 19 258
Miriam Hobbs United States 7 139 1.2× 129 1.6× 11 0.2× 75 1.3× 7 0.1× 26 225
Weiying Gu China 10 58 0.5× 95 1.2× 10 0.2× 28 0.5× 36 0.7× 35 247
Chang‐Liang Lai Taiwan 7 347 3.1× 169 2.1× 8 0.1× 161 2.9× 32 0.6× 10 408

Countries citing papers authored by Yingwan Luo

Since Specialization
Citations

This map shows the geographic impact of Yingwan Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingwan Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingwan Luo more than expected).

Fields of papers citing papers by Yingwan Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingwan Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingwan Luo. The network helps show where Yingwan Luo may publish in the future.

Co-authorship network of co-authors of Yingwan Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Yingwan Luo. A scholar is included among the top collaborators of Yingwan Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yingwan Luo. Yingwan Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Wei, Yudi Zhang, Wenli Yang, et al.. (2025). The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes. Journal of Translational Medicine. 23(1). 76–76.
2.
Luo, Yingwan, Xiaomin Feng, Wei Lang, et al.. (2024). Ectopic expression of the transcription factor ONECUT3 drives a complex karyotype in myelodysplastic syndromes. Journal of Clinical Investigation. 134(8). 1 indexed citations
3.
Lang, Wei, Yingwan Luo, Lu Wang, et al.. (2024). The der(1;7)(q10;p10) defining a distinct profile from −7/del(7q) in myelodysplastic syndromes: A systematic review and meta‐analysis. Cancer Medicine. 13(1). e6890–e6890. 1 indexed citations
4.
Zhang, Yudi, Jiejing Qian, Xinping Zhou, et al.. (2024). The m6A methyltransferase METTL14 promotes cell proliferation via SETBP1-mediated activation of PI3K-AKT signaling pathway in myelodysplastic neoplasms. Leukemia. 38(10). 2246–2258. 5 indexed citations
5.
Hu, Long, Yingwan Luo, Miao Wang, et al.. (2023). Identification of apoptosis-related key genes and the associated regulation mechanism in thoracic aortic aneurysm. BMC Cardiovascular Disorders. 23(1). 481–481.
6.
7.
Ye, Li, Liya Ma, Yanling Ren, et al.. (2022). Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology. 148(4). 845–856. 6 indexed citations
8.
9.
Ren, Yanling, Wei Lang, Chen Mei, et al.. (2022). Co‐mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome. Hematological Oncology. 41(1). 159–166. 7 indexed citations
10.
Luo, Yingwan, Lu Wang, Liya Ma, et al.. (2019). Mutation status and burden can improve prognostic prediction of patients with lower‐risk myelodysplastic syndromes. Cancer Science. 111(2). 580–591. 29 indexed citations
11.
Ye, Li, Yanling Ren, Xinping Zhou, et al.. (2019). Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy. Blood Cells Molecules and Diseases. 77. 88–94. 4 indexed citations
12.
Luo, Yingwan, et al.. (2019). Mutation Status and Burden Can Improve Prognostic Prediction of Patients with Lower-Risk Myelodysplastic Syndromes. Blood. 134(Supplement_1). 3008–3008. 6 indexed citations
13.
Ren, Yanling, Li Ye, Yingwan Luo, et al.. (2019). Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting. Leukemia & lymphoma. 60(7). 1731–1739. 3 indexed citations
14.
Lin, Peipei, Yingwan Luo, Dominic Maggio, et al.. (2018). Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology. 144(6). 1037–1047. 17 indexed citations
15.
Sun, Chuanyin, et al.. (2018). Usefulness of tocilizumab for treating rheumatoid arthritis with myelodysplastic syndrome. Medicine. 97(25). e11179–e11179. 5 indexed citations
16.
Ren, Yanling, Chen Mei, Li Ye, et al.. (2018). Analysis of clinical and molecular features of MDS patients with complex karyotype in China. Blood Cells Molecules and Diseases. 75. 13–19. 9 indexed citations
17.
Ma, Liya, Yingwan Luo, Dan Shen, et al.. (2018). The relation ofSF3B1mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts. Leukemia & lymphoma. 60(5). 1179–1186. 3 indexed citations
18.
Ye, Li, Yanling Ren, Lili Xie, et al.. (2017). [A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].. PubMed. 38(4). 307–312. 1 indexed citations
19.
Lin, Xianfeng, Keqing Shi, Jie You, et al.. (2014). Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Molecular Biology Reports. 41(5). 2989–2997. 56 indexed citations
20.
Zheng, Ming‐Hua, Yu Li, Dongdong Xiao, et al.. (2012). Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians. Gene. 518(2). 479–482. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Hosius Breakdown of academic impact, for papers by Samuel Quentin Breakdown of academic impact, for papers by Carlos Hader Breakdown of academic impact, for papers by Oriana Miltiadous Breakdown of academic impact, for papers by Sheng‐Chieh Chou Breakdown of academic impact, for papers by Yazan Migdady Breakdown of academic impact, for papers by Yusuke Shiozawa Breakdown of academic impact, for papers by Miriam Hobbs Breakdown of academic impact, for papers by Weiying Gu Breakdown of academic impact, for papers by Chang‐Liang Lai
Rankless by CCL
2026